The collaboration will use multi-omic platforms and AI-driven analytics to identify disease patterns and improve patient stratification within the PRECISE-SG100K study.

Thermo Fisher Scientific and Precision Health Research, Singapore (PRECISE), announced a collaboration to advance the PRECISE-SG100K study, a population-scale biobank initiative in the region. The partnership aims to use proteomics to gain insights into real-time disease biology for applications in earlier detection, prevention, and personalized care.

As biobanks become central to national health strategies, the integration of multi-omic platforms and artificial intelligence (AI)-driven analytics is considered critical, according to a release from Thermo Fisher. When applied to proteomic and clinical data, AI can identify biological patterns, improve patient stratification, and accelerate the transition from discovery to translational insight.

“Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health,” says Marc N. Casper, chairman and chief executive officer of Thermo Fisher, in a release. “By combining our deep scientific expertise with industry-leading technologies, we are helping national health leaders translate complex biological data into insights that can fundamentally transform human health.”

Integrated Proteomics Strategy

Under the program, Thermo Fisher will deploy an integrated proteomics strategy. This includes the Olink Proximity Extension Assay platforms and the high-resolution Orbitrap Astral mass spectrometry system. The project also utilizes the Seer Proteograph Product Suite to provide scalable, high-sensitivity protein measurement and discovery proteomics.

The PRECISE-SG100K study is a longitudinal population cohort designed to strengthen reproducibility and support regulatory-grade evidence generation. This model reflects the growing use of proteomics as foundational research infrastructure for precision medicine.

“National biobank initiatives require technologies that deliver both breadth and precision,” says Karen Nelson, chief scientific officer at Thermo Fisher, in a release. “By integrating our differentiated technologies, we are enabling high-confidence biomarker identification and accelerating the path to translational application. This complementary strategy sets a new standard for multi-proteomics analysis and empowers researchers to see true disease biology with speed and at scale.”

Global Biobank Context

Thermo Fisher is currently involved in several large-scale biobank efforts, including the UK Biobank Pharma Proteomics Project, FinnGen in Finland, and the Geisinger MyCode Community Health Initiative in the United States. Collectively, these programs involve the analysis of more than 1 million samples.

Comparing data from these complementary platforms with public proteomic datasets from other global studies provides researchers with the capacity for discovery, validation, and accelerated translation.

“By applying this integrated proteomics approach across our national cohort, we gain a dynamic view of disease biology within Singapore’s uniquely diverse population,” says John Chambers, chief scientific officer at PRECISE and lead principal investigator of the PRECISE-SG100K study, in a release. “This model strengthens our ability to uncover early molecular signals of disease, understand risk across different global communities, and generate insights that can inform the future of population health.”

The study is supported by Seer Inc as a research collaboration partner and by Novogene, which provides laboratory services for sample processing and data generation.

ID 95803846 © Woraphon Banchobdi | Dreamstime.com

Related Reading: